Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

20 Oct 2017

Abstract excerpt

Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29070816
DOI: 10.1038/s41467-017-01062-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to checkpoint blockade therapy through inactivation of antigen presentationPMID 29070816Read ↗

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.Semantic proximity Read ↗

The molecular and functional landscape of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitorsSemantic proximity Read ↗

Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibitionSemantic proximity Read ↗

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.Semantic proximity Read ↗

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadeSemantic proximity Read ↗

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy ResponseSemantic proximity Read ↗

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.Semantic proximity Read ↗

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.Semantic proximity Read ↗

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.